|
Press Releases |
|
 |
|
Tuesday, March 14, 2023 |
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
Friday, March 10, 2023 |
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
Thursday, March 9, 2023 |
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 6, 2023 |
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
Thursday, March 2, 2023 |
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
Tuesday, February 28, 2023 |
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
Tuesday, February 21, 2023 |
|
Dissolution of Bracco-Eisai Joint Venture |
Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. more info >> |
|
Monday, January 30, 2023 |
|
Lecanemab Receives Priority Review Status in Japan |
Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
Friday, January 27, 2023 |
|
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency |
Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline. more info >> |
|
Thursday, January 19, 2023 |
|
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel |
Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Wintermar Offshore (WINS:JK) Reports 1Q2025 Results
Apr 28, 2025 11:25 HKT/SGT
|
|
|
Philippines Job Market Records 11% Annual Growth Despite Recent Hiring Slowdown
Apr 28, 2025 09:30 HKT/SGT
|
|
|
HKTDC's April lifestyle fairs open today
Apr 27, 2025 19:42 HKT/SGT
|
|
|
Strengthening Hong Kong-Zhejiang Ties: The Hong Kong Investment Promotion - Zhejiang Ningbo Forum
Apr 26, 2025 21:40 HKT/SGT
|
|
|
Strengthening Hong Kong-Zhejiang Ties
Apr 25, 2025 21:05 HKT/SGT
|
|
|
Graphene Manufacturing Group Provides Quarterly ATM Sales Update
Apr 25, 2025 20:29 HKT/SGT
|
|
|
NEC achieves Japan's longest terrestrial wireless optical communication over 10 km
Apr 25, 2025 17:50 JST
|
|
|
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Apr 25, 2025 15:49 HKT/SGT
|
|
|
Edvantage Group Announces FY2025 Interim Results
Apr 25, 2025 14:40 HKT/SGT
|
|
|
Olympus Appoints New CEO
Apr 25, 2025 15:30 JST
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Year Ended 31 December 2024
Apr 25, 2025 13:17 HKT/SGT
|
|
|
DENSO Announces Year-End Financial Results
Apr 25, 2025 12:17 JST
|
|
|
Mooreast Holdings Announces Business Update
Apr 25, 2025 10:00 HKT/SGT
|
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025
Apr 24, 2025 18:43 HKT/SGT
|
|
|
DENSO and DELPHY Sign Memorandum of Understanding to Develop Data-Driven Smart Horticulture
Apr 24, 2025 18:43 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|